Biogen Inc. ($BIIB) Stock Forecast: Up 5.0% Today

What is Biogen Inc.?

Biogen (BIIB) is a leading biotechnology company known for its innovative treatments in various therapeutic areas, including neurology and immunology. Today, BIIB experienced a strong bullish movement in the stock market.

Why is Biogen Inc. going up?

BIIB stock is up 5.0% on Jun 4, 2026 14:26

• BIIB's stock surged as the FDA granted Breakthrough Therapy Designation to its investigational antisense oligonucleotide, salanersen, for spinal muscular atrophy (SMA), signaling potential future market growth for BIIB.
• Despite a setback in its Parkinson's disease pipeline with BIIB122 failing its Phase 2b trial, the positive Phase 3 results for dapirolizumab pegol in lupus highlighted BIIB's strength in immunology, maintaining a balanced investment narrative.
• The broader rally in the biotechnology sector, alongside peer companies like Exelixis, Incyte, and Moderna, contributed to BIIB's bullish movement, showcasing a shift in investor sentiment towards growth-oriented healthcare entities.
• The ongoing legal battle involving Randgold & Exploration (R&E) and Gold Fields, although significant in the mining industry, did not directly impact BIIB's market performance today.

BIIB Price Chart

BIIB Technical Analysis

BIIB News

Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy

Biogen's salanersen has received FDA Breakthrough Therapy Designation for spinal muscular atrophy (SMA), supported by Phase 1b data showing clinically meaningful improvements in motor function and slowing of neurodegeneration in children previously treated with gene therapy. Salanersen is an investigational antisense oligonucleotide with once-yearly dosing, now advancing into Phase 3 studies to address unmet needs in the SMA community.

https://www.globenewswire.com/news-release/2026/06/04/3306663/0/en/biogen-s-salanersen-receives-fda-breakthrough-therapy-designation-for-spinal-muscular-atrophy.html

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

New data presented at EULAR 2026 from the Phase 3 PHOENYCS GO study indicate that dapirolizumab pegol (DZP) can reduce flare rates and maintain disease control in systemic lupus erythematosus (SLE) patients, allowing for lower glucocorticoid doses. This investigational biologic, developed by UCB and Biogen, also showed improvements in immunological markers and a generally favorable safety profile. The findings highlight DZP's potential to address the complex burden of SLE by enabling steroid tapering while minimizing long-term steroid exposure and maintaining disease control.

https://www.globenewswire.com/news-release/2026/06/04/3306500/0/en/eular-2026-dapirolizumab-pegol-shows-potential-to-reduce-flare-rates-and-maintain-disease-control-in-systemic-lupus-erythematosus.html

The hunt for the Kebble millions

More than two decades after mining magnate Brett Kebble was shot dead, his messy legacy continues to impact South African mining, with Randgold & Exploration (R&E) pursuing a multi-billion rand claim against Gold Fields. The legal battle centers on alleged misappropriated shares and the value of these shares, which has inflated significantly due to rising gold prices. The case highlights the complexities of corporate fraud, the prolonged nature of high-stakes litigation, and the potential for a substantial settlement that could benefit R&E shareholders.

https://www.financialmail.businessday.co.za/features/2026-06-04-the-hunt-for-the-kebble-millions/

Mixed Lupus Win And Parkinson’s Setback Might Change The Case For Investing In Biogen (BIIB)

Biogen (BIIB) received mixed news in its pipeline, with positive Phase 3 results for dapirolizumab pegol in lupus but a setback in Parkinson's disease with BIIB122 failing its Phase 2b trial. This information rebalances Biogen's investment narrative, emphasizing its growing immunology efforts while highlighting the concentration risk in a few high-profile launches. Investors should consider how new autoimmune assets might offset neurodegeneration setbacks and competition in existing markets.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-biib/biogen/news/mixed-lupus-win-and-parkinsons-setback-might-change-the-case

Exelixis Jumps 5.0% Amid Sector-Wide Rally

Exelixis, Inc. saw its stock price surge by 5.0% to $50.99 on Wednesday, driven by a broader rally in the biotechnology sector. This rise, which included similar gains for several peer companies like Incyte and Moderna, was attributed to sector-wide momentum rather than any specific company news. The coordinated movement suggests a shift in investor sentiment towards growth-oriented healthcare names, pushing Exelixis's market capitalization to $12.8 billion.

https://news.alphastreet.com/exelixis-jumps-5-0-amid-sector-wide-rally/

Trending Today

Align Technology Inc. ($ALGN) Stock Forecast: Up 5.2% Today

Grab Holdings Limited ($GRAB) Stock Forecast: Up 7.1% Today

Electronic Arts Inc. ($EA) Stock Forecast: Down 0.4% Today

ARM Holdings plc ($ARM) Stock Forecast: Up 5.0% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Up 5.1% Today

Reddit Inc ($RDDT) Stock Forecast: Up 5.0% Today

Analog Devices Inc. ($ADI) Stock Forecast: Up 5.6% Today

Stitch Fix Inc. ($SFIX) Stock Forecast: Up 5.2% Today

Corsair Gaming Inc. ($CRSR) Stock Forecast: Up 5.6% Today

Dollar Tree Inc. ($DLTR) Stock Forecast: Up 5.3% Today

Biogen Inc. Price History

31.02.2026 - BIIB Stock was down 5.6%

• The bearish movement in Biogen's stock price is possibly linked to the market's response to its acquisition of Apellis Pharmaceuticals for $5.6 billion. Concerns from analysts regarding the premium paid and competitive environment could be contributing to investor skepticism, despite the potential advantages of acquiring two approved medications and expertise in the nephrology sector.
• Biogen's strategic move to diversify its product portfolio and hasten the market entry of its new kidney disease drug, felzartamab, through the acquisition of Apellis Pharmaceuticals might be facing uncertainty from the market in terms of immediate financial impact and long-term growth prospects.
• The surge in Apellis Pharmaceuticals' stock value following the acquisition announcement presents a positive market sentiment toward the deal, contrasting with the volatility in Biogen's stock price. This disparity in market reactions between the two companies involved could be influencing Biogen's stock movement.
• Investors interested in Biogen are likely keeping a close watch on the company's future financial reports and strategic initiatives to evaluate the success of the acquisition and its potential effects on Biogen's overall performance in upcoming quarters.

31.02.2026 - BIIB Stock was down 5.0%

• Biogen's bearish movement today could be attributed to the announcement of its acquisition of Apellis Pharmaceuticals for $5.6 billion. While acquisitions are often seen as a strategic move to expand the company's portfolio, the market may have reacted negatively due to concerns about the integration process and the potential impact on Biogen's financials.
• The news of Stryker promoting key finance executives may have also influenced investor sentiment, as leadership changes within a company can sometimes create uncertainty about future financial strategies and performance.
• Additionally, the overall market sentiment towards biotech stocks and the broader economic conditions could have contributed to the bearish movement in Biogen's stock today. Investors may be cautious amid market volatility and global economic uncertainties.

31.02.2026 - BIIB Stock was down 5.2%

• Biogen's stock experienced a bearish movement as the market reacted negatively to the news of its intent to acquire Apellis Pharmaceuticals for $5.6 billion.
• The acquisition is seen as a strategic move to enhance Biogen's immunology and rare disease portfolio with Apellis's FDA-approved therapies, but investors may have concerns about the hefty price tag and potential integration challenges.
• The market might be cautious about the impact of this acquisition on Biogen's financials, revenue, and adjusted earnings per share starting in 2027, leading to the bearish trend.
• Investors are likely monitoring how Biogen navigates this acquisition and integrates Apellis's assets into its existing portfolio to gauge the long-term impact on the company's growth prospects.

27.02.2026 - BIIB Stock was down 2.5%

• The decline in Biogen's stock value possibly stemmed from Vanguard's recent disclosure of holding zero shares and beneficial ownership of Biogen. This change in investment interest could have prompted investor apprehension, leading to a sell-off.
• Positive growth predictions in the Anca Vasculitis Drug Market and emerging therapies in the Spinal Muscular Atrophy Pipeline might have momentarily diverted investor attention from Biogen, negatively affecting its stock performance.
• The financial outcomes and strategic advancements reported by MapLight Therapeutics, such as upcoming Phase 2 study outcomes, may have redirected investor focus towards other biotech firms, influencing Biogen's stock downward.
• Although the collaboration between Biogen and Alteogen Inc. presented optimistic prospects for Biogen, it might not have sufficed to counter prevailing market sentiments and incite a bullish upturn in the stock on the given day.

06.01.2026 - BIIB Stock was up 2.4%

• BIIB stock surged today, hitting a 52-week high at $190.34, marking a 31.14% rise in the past year and a 43.31% gain in the last six months.
• The positive market response follows Biogen's strong Q4 2025 financial performance, surpassing revenue projections and beating analyst estimates for non-GAAP EPS.
• Biogen's strategic focus on its at-home Alzheimer’s drug, successful trial outcomes for multiple treatments, and receipt of FDA Breakthrough Therapy Designation have boosted investor confidence in the company's future growth prospects.
• Despite revenue challenges from declining multiple sclerosis treatments, Biogen's optimistic 2026 outlook, emphasis on neurodegenerative and rare diseases, and favorable valuation based on financial metrics have bolstered investor trust and fueled the stock's upward trajectory.

06.01.2026 - BIIB Stock was up 6.9%

• Biogen's stock demonstrated significant upward momentum, reaching a 52-week high, following the release of impressive fourth-quarter earnings and revenues, attributed to the notable sales growth of its Alzheimer's medication Leqembi.
• The company's strategic shift from a primary emphasis on multiple sclerosis to establishing itself as a key player in neuro-innovation, with successful treatments like Skyclarys and Leqembi, has amplified investor confidence and positively impacted the stock's performance.
• Biogen's perceived undervaluation, evidenced by a P/E ratio of 16.92 and a robust free cash flow yield of 8%, alongside favorable developments such as FDA recognitions and successful trial outcomes, has further bolstered the optimistic outlook surrounding the stock.
• Biogen's adept navigation of obstacles, including regulatory complexities and market competition, in conjunction with its growth-oriented approach through collaborations and a diversified product pipeline, highlights its potential for long-term success in the dynamic biopharmaceutical sector.

25.01.2026 - BIIB Stock was down 2.5%

• The downward trend in BIIB's stock price today may be linked to a trade secrets lawsuit and a dismissal motion filed by Definium Therapeutics Inc., resulting in uncertainty and legal concerns.
• Market sentiment could also be influenced by the struggles of other biotech firms such as Avidity Biosciences, which reported significant financial losses, leading to doubts about the sector's financial performance and future growth.
• Furthermore, the FDA's rejection of Alvotech's biologics license application due to facility issues and the subsequent legal investigation could have raised apprehensions about regulatory challenges in the biotech industry, impacting attitudes towards companies like BIIB.

29.03.2026 - BIIB Stock was up 5.5%

• Biogen Inc. (BIIB) surpassed Q1 earnings and revenue expectations, indicating strong financial performance.
• The company's recent announcement to acquire Apellis Pharmaceuticals for $5.6 billion illustrates strategic expansion strategies.
• Despite revising its earnings guidance downwards, Biogen's favorable clinical trial outcomes and regulatory approvals suggest ongoing growth opportunities.
• The market sentiment towards BIIB may have benefited from Ionis Pharmaceuticals' successful initiatives such as TRYNGOLZA and DAWNZERA, given the companies' shared emphasis on innovative therapies.

29.03.2026 - BIIB Stock was up 6.6%

• BIIB stock experienced a strong bullish movement following the company's impressive Q1 earnings report, surpassing both earnings per share (EPS) and revenue estimates.
• The announcement of Biogen's plans to acquire Apellis Pharmaceuticals for $5.6 billion further boosted investor confidence in the company's growth strategy and expansion of its portfolio.
• Despite the positive performance, Biogen revised its full-year earnings outlook downwards due to increased costs associated with business development activities, signaling a cautious approach amidst its ambitious growth plans.
• The market's reaction indicates that investors are optimistic about Biogen's future prospects, driven by its strong financial performance and strategic acquisitions in the biopharmaceutical sector.

14.04.2026 - BIIB Stock was down 5.0%

• Biogen's stock fell despite positive signs from its diranersen Alzheimer's drug trial, which showed cognitive benefit and tau reductions but missed its primary endpoint. This mixed outcome likely led to investor disappointment and profit-taking.
• The completion of Biogen's acquisition of Apellis Pharmaceuticals, although adding two commercial drugs to its portfolio, might have raised concerns about integration challenges or market uncertainties, contributing to the bearish sentiment.
• The market may have reacted negatively to the news, as investors were cautiously optimistic about the drug's potential for advancement, and any slight setbacks could have triggered a sell-off in the stock.
• Overall, the combination of the trial results and acquisition completion likely created uncertainty and volatility in Biogen's stock, leading to the bearish movement observed today.

14.04.2026 - BIIB Stock was down 3.5%

• The completion of Biogen's acquisition of Apellis Pharmaceuticals, which included purchasing at $41 per share along with Contingent Value Rights (CVRs), potentially sparked investor worries about the financial consequences and integration obstacles of the agreement.
• Despite the possible growth opportunities from incorporating Apellis's products EMPAVELI and SYFOVRE, investors may be exercising caution due to uncertainties surrounding the attainment of future milestones and sales objectives linked to the CVRs.
• The announcement of securing $2 billion in term loan facilities to fund the acquisition might have prompted concerns regarding Biogen's debt levels and its financial flexibility, contributing to the negative market movement.
• The removal of Apellis's stock from Nasdaq post-merger could have affected investor sentiment, resulting in the selling pressure on BIIB shares as the market evaluates the impact of the acquisition.

04.05.2026 - BIIB Stock was up 5.0%

• BIIB's stock surged as the FDA granted Breakthrough Therapy Designation to its investigational antisense oligonucleotide, salanersen, for spinal muscular atrophy (SMA), signaling potential future market growth for BIIB.
• Despite a setback in its Parkinson's disease pipeline with BIIB122 failing its Phase 2b trial, the positive Phase 3 results for dapirolizumab pegol in lupus highlighted BIIB's strength in immunology, maintaining a balanced investment narrative.
• The broader rally in the biotechnology sector, alongside peer companies like Exelixis, Incyte, and Moderna, contributed to BIIB's bullish movement, showcasing a shift in investor sentiment towards growth-oriented healthcare entities.
• The ongoing legal battle involving Randgold & Exploration (R&E) and Gold Fields, although significant in the mining industry, did not directly impact BIIB's market performance today.